ConSynance Therapeutics is a clinical-stage biopharmaceutical company focused on addressing the neuropsychiatric aspects of rare central nervous system (CNS) diseases.  We are dedicated to transforming breakthrough scientific discoveries into life-changing therapies, with a current focus on conditions related to hypothalamic dysregulation, including Prader-Willi Syndrome, hypothalamic injury-induced obesity, and related disorders.